RESUMO
PURPOSE: Vaginal cylinder high-dose-rate (HDR) brachytherapy is currently one of the most common procedures performed in the treatment of early-stage endometrial cancer. However, current recommendations by the American Brachytherapy Society regarding fractional re-imaging and dose calculation for organs at risk for HDR vaginal cuff brachytherapy are not well defined. In this study, we aim to compare a fractional re-imaging approach using computed tomographic (CT) scans prior to each fraction with a first fraction imaging-only approach with respect to bladder, rectal, and bowel dosimetry. METHODS AND MATERIALS: Nineteen endometrial cancer patients undergoing vaginal cuff brachytherapy for endometrial cancer were imaged with CT scanning prior to every HDR fraction (fractional re-imaging [FRI]). Dose to the bowel, bladder, and rectum were calculated and compared with the estimated dose if imaging and planning were done only on the first fraction (first fraction imaging [FFI]). RESULTS: In the analysis of FFI versus FRI, we observed mean bladder doses of 8.34 Gy vs 8.33 Gy (P = .98), mean rectal doses of 12.19 Gy versus 12.14 Gy (P = .81), and mean bowel doses of 2.82 Gy versus 2.76 Gy (P = .81). The FFI approach underestimated the FRI doses to the bladder, rectum, and bowel by 20% or more in 11%, 5%, and 29% of patients, respectively. Cost analysis revealed an estimated $663.06, or a 35% savings per patient treated with FFI. CONCLUSIONS: There is no statistically significant difference in the mean dose to the bladder, rectum, or bowel in patients undergoing HDR vaginal cuff brachytherapy with a first fraction imaging scheme versus a fractional re-imaging scheme. These results indicate that fractional re-imaging is not necessary except in patients whose estimated dose to critical organs is near the maximum limit.
RESUMO
PURPOSE: To compare computed tomography (CT) with positron emission tomography-CT (PET-CT) scans with respect to anorectal tumor volumes, correlation in overlap, and influence on radiation treatment fields and patient care. PATIENTS AND METHODS: From March to November 2003, 20 patients with rectal cancer and 3 patients with anal cancer were treated with preoperative or definitive chemoradiation, respectively. Computed tomography simulation data generated a CT gross tumor volume (CT-GTV) and CT planning target volume (CT-PTV) and (18)F-fluoro-2-deoxy-glucose PET (FDG-PET) created a PET-GTV and PET-PTV. The PET-CT and CT images were fused using manual coregistration. Patients were treated with three-dimensional conformal therapy to traditional doses. The PET, CT, and overlap volumes (OVs) were measured in cubic centimeters. RESULTS: Mean PET-GTV was smaller than the mean CT-GTV (91.7 vs. 99.6 cm(3)). The mean OV was 46.7%. As tumor volume increased, PET and CT OV correlated significantly (p < 0.001). In 17% of patients PET-CT altered the PTV, and in 26% it changed the radiation treatment plan. For 25% of patients with rectal cancer, PET detected distant metastases and changed overall management. Ten rectal cancer patients underwent surgery. When the pretreatment PET standardized uptake value was >10 and the posttreatment PET standardized uptake value was <6, 100% achieved pathologic downstaging (p = 0.047). CONCLUSIONS: Variation in volume was significant, with 17% and 26% of patients requiring a change in treatment fields and patient management, respectively. Positron emission tomography can change the management for anorectal tumors by early detection of metastatic disease or disease outside standard radiation fields.